Medical Oncologist
Hereditary cancer risk
PALB2, ATM, CHEK2 and MUTYH: — What Your Mutation Actually Means
Finding a mutation in one of these four genes raises your cancer risk — but not to the same level as BRCA1 or BRCA2. Each gene has its own risk profile and its own screening schedule, and both of those things change what you do next.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Not BRCA-level risk — These genes raise risk meaningfully but sit below BRCA1 and BRCA2 on the scale of inherited cancer risk.
- Each gene is different — PALB2 mainly affects breast cancer risk. MUTYH mainly affects the bowel. ATM and CHEK2 affect breast cancer risk at a lower level than PALB2.
- Screening starts earlier — Knowing your gene means starting breast or bowel surveillance earlier than the general population — sometimes by a decade or more.
- Your relatives need to know — Each of these mutations runs in families. First-degree relatives have a meaningful chance of carrying the same change.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
A PALB2 mutation raises your lifetime breast cancer risk significantly above average — NCCN and ASCO guidance puts this in the range of one in three to one in two. ATM, CHEK2 and MUTYH raise risk less sharply. All four genes have established screening protocols. Knowing you carry one means earlier, more structured monitoring.
What does a PALB2 mutation mean for my cancer risk?
PALB2 carries the highest breast cancer risk of the four genes on this page. NCCN and ASCO guidance places the lifetime risk in the range of one in three to one in two. The exact figure for any individual depends on family history and the specific variant carried.
ATM and CHEK2 each raise lifetime breast cancer risk above what is expected in women without a hereditary variant. NCCN places the lifetime risk for both ATM and CHEK2 broadly in the range of one in five to one in four.
MUTYH works differently. Carrying one changed copy (monoallelic) gives a modest increase in colorectal cancer risk. Carrying two changed copies (biallelic) raises colorectal cancer risk substantially — NCCN guidance places the lifetime figure in the range of four in ten to six in ten, depending on which variants you carry.
None of these mutations makes cancer certain. They raise the probability. Knowing about them means you can act on that probability with earlier, more structured monitoring.
What should I do now after a positive result?
- See a genetic counsellor if you have not alreadyA positive result needs interpretation in the context of your personal history, family history, and specific variant. A genetic counsellor does that — and coordinates what comes next.
- Tell your oncologist or GP in writingYour treating team needs the result documented so that any care decisions — including surveillance, surgery, and referrals — take it into account.
- Share the result with first-degree relativesEach parent, sibling, and child has a meaningful chance of carrying the same mutation. Early knowledge gives them the option to test and act before a cancer develops.
- Get the gene-specific screening plan — not a generic oneEach of these four genes has a different protocol. Ask your team explicitly which schedule applies to your gene.
- Keep a copy of the written genetic reportStore it somewhere accessible. It states your specific variant, which is what future doctors — and your relatives' doctors — will need to see.
- Ask about risk-reduction optionsSurveillance is not the only option for some of these mutations. Ask whether chemoprevention or other strategies apply to your gene and your situation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
When should screening start, gene by gene?
MUTYH biallelic — colonoscopy from around age 25 to 30
If you carry two changed copies of MUTYH, NCCN guidance supports colonoscopy beginning in your mid-to-late twenties, with repeat examinations every one to two years depending on findings. This is substantially earlier than standard population bowel screening.
PALB2 — breast imaging from around age 30
Annual breast MRI alongside annual mammography is the approach NCCN recommends for PALB2 carriers, starting at 30 or ten years before the youngest affected relative's age at diagnosis — whichever is earlier. Discuss risk-reducing options with your team from around age 35 to 40.
ATM and CHEK2 — breast imaging from around age 40
NCCN and ASCO support annual mammography from age 40 for both ATM and CHEK2 carriers, with consideration of annual breast MRI alongside it. If your family history includes diagnoses in the thirties, your team may bring this start date forward.
CHEK2 — bowel screening from around age 40
CHEK2 also carries a moderately elevated colorectal cancer risk. Colonoscopy from 40, with repeat examinations every three to five years, is consistent with NCCN and ASCO guidance for this gene.
MUTYH monoallelic — bowel screening from no later than age 40
One changed MUTYH copy carries a lower colorectal cancer risk than two. NCCN guidance supports colonoscopy beginning no later than 40, with intervals determined by your findings and family history.
Every gene — annual clinical review
Guidance for moderate-risk genes is updated as new evidence accumulates. An annual review ensures your plan reflects current recommendations, any change in your family history, and any new risk-reduction options.
Does my family need to be tested because of my result?
Yes — and testing relatives is often the most immediately useful thing that follows from your positive result. PALB2, ATM and CHEK2 are each inherited in an autosomal dominant pattern, meaning every first-degree relative has roughly a one in two chance of carrying the same mutation.
MUTYH is different. It is autosomal recessive. Most monoallelic carriers inherited one changed copy from one parent. A child of two monoallelic carriers can inherit both copies and carry the higher biallelic risk — so the family history, not just the individual result, shapes the urgency of relative testing.
A relative who tests negative for your specific variant can follow the standard population screening schedule. A relative who tests positive begins the same earlier surveillance you are following.
Genetic counselling and relative testing is available through cancer genetics services at tertiary centres in Telangana and Andhra Pradesh. Your counsellor can provide the documentation a relative needs to access testing through their own team.
Explore 113 more Family, Fertility, Diet & Emotional Wellbeing topics
Genetic Predisposition & Family Risk
- BRCA Testing in India: Cost, Process and Where to Get It Done
- Cascade Testing: Getting Your Family Members Tested
- Coping With the Anxiety of a Positive Genetic Test
- Does a BRCA Mutation Mean You Will Definitely Get Cancer?
- Family History of Cancer: Should You Get Genetic Testing?
- Genetic Counselling: What Actually Happens in the Session
- Hereditary Diffuse Gastric Cancer and the CDH1 Gene
- How to Tell Your Children and Siblings About a Genetic Risk
- I'm BRCA Positive but Have No Cancer: What Happens Now?
- IVF and Preimplantation Testing to Avoid Passing On a Mutation
- Li-Fraumeni Syndrome: Living With a TP53 Mutation
- Lynch Syndrome: Cancers, Screening and Treatment Implications
- MEN2, VHL and Other Endocrine Cancer Syndromes
- MUTYH, PALB2, ATM and CHEK2: Moderate-Risk Genes Explained
- Male BRCA Carriers: The Risks Nobody Talks About
- PARP Inhibitors: How a Genetic Mutation Becomes a Treatment Advantage
- Risk-Reducing Mastectomy: How to Decide
- Risk-Reducing Ovary and Tube Removal: Timing and Consequences
- Somatic Mutation Found on NGS: Could It Be Inherited?
- Surveillance Instead of Surgery: What Screening Looks Like
- Which Family Histories Actually Suggest a Hereditary Cancer Syndrome?
- Will a Genetic Test Result Affect Your Insurance in India?
Caregiver Enablement
- Building a Care Roster When One Person Can't Do It All
- Caregiver Burnout: Recognising It Before It Breaks You
- Caregiver Red Flag Chart: When to Take Them to Hospital
- Caring for an Elderly Parent on Oral Cancer Tablets
- Cooking for Someone on Targeted Therapy: A Kitchen Guide
- Coordinating Care From Abroad: A Guide for NRI Families
- Financial Management for Caregivers: Bills, Claims and Records
- How to Get a Second Opinion Without Offending Your Doctor
- How to Track Side Effects: A Simple Daily Diary System
- Managing Medicines, Refills and Pharmacy Runs
- Questions Every Caregiver Should Ask at the Oncology Visit
- Supporting Someone Emotionally Without Saying the Wrong Thing
- The Complete Caregiver's Guide to Targeted Therapy
- What to Do When the Patient Refuses to Take Their Medicine
Diet, Nutrition & Complementary Therapy
- Ayurveda Alongside Targeted Therapy: An Honest Assessment
- Do Immunity Boosters Help During Cancer Treatment?
- Does Sugar Feed Cancer? Separating Myth From Fact
- Eating With Mouth Sores: Foods That Don't Hurt
- Eating to Control High Blood Sugar From Cancer Drugs
- Food Safety and Hygiene for Cancer Patients at Home
- Foods to Avoid on Targeted Therapy
- How Much Protein Does a Cancer Patient Actually Need?
- Hydration: How Much Water and What Counts
- Is Cow's Milk, Soya or Non-Veg Food Safe During Cancer Treatment?
- Keto and Intermittent Fasting During Cancer Treatment: Is It Safe?
- Managing Weight Loss and Muscle Wasting
- What Should You Eat While on Targeted Therapy? A Practical Indian Diet Guide
- What to Eat When You Have Diarrhoea From Cancer Tablets
- Yoga and Pranayama During Cancer Treatment
Fertility, Pregnancy & Sexual Health
- Accidental Pregnancy While on Targeted Therapy: What Now?
- Can You Breastfeed While on Targeted Therapy?
- Cancer Diagnosed During Pregnancy: Can Targeted Therapy Be Used?
- Contraception on Targeted Therapy: Which Methods Are Safe?
- Early Menopause Caused by Cancer Treatment
- Erectile Dysfunction and Sexual Changes in Men on Treatment
- Fertility After Long-Term Targeted Therapy: What the Data Shows
- Fertility Preservation Before Starting Treatment: Your Options and Timeline
- How Long Must You Wait Before Trying to Conceive?
- Sperm Banking Before Cancer Treatment: A Practical Guide
- Talking to Your Partner About Sex During Cancer Treatment
- Vaginal Dryness, Pain and Low Libido During Treatment
- Will Targeted Therapy Affect My Fertility?
Mental Health & Emotional Wellbeing
- Body Image When Your Skin, Nails and Hair Change
- Cancer Support Groups in India: How to Find One
- Depression During Long-Term Cancer Treatment
- Handling Unhelpful Advice and Toxic Positivity
- Living With Cancer as a Chronic Disease: A New Identity
- Sleep, Anxiety and Night-Time Fear During Treatment
- Talking to Your Children About Your Cancer Diagnosis
- Telling Friends, Relatives and Neighbours: How Much to Share
- The Fear That the Drug Will Stop Working: How to Live With It
- When Should You See a Psycho-Oncologist?
Myths, Misinformation & Verification
- Are Generic Cancer Drugs Fake or Weaker?
- Can Cancer Be Cured Without Any Modern Medicine?
- Cannabis and CBD Oil for Cancer: What the Evidence Actually Says
- Does Soursop, Apricot Seed or Alkaline Water Cure Cancer?
- Does a Biopsy Spread Cancer?
- How to Fact-Check Cancer Information You Read Online or From AI
- Miracle Cancer Cures on WhatsApp and YouTube: How to Spot a Fake
- Myth: Cancer Treatment Is Worse Than the Disease
- Myth: If the Scan Is Clear You Can Stop the Tablets
- Myth: Positive Thinking Cures Cancer
- Myth: Sugar, Milk or Non-Veg Food Feeds Cancer
- Myth: Targeted Therapy Has No Side Effects
- Myth: Targeted Therapy Is Only for the Rich
Palliative Care & End of Life
- Breathlessness and Comfort Care in Advanced Cancer
- Hospice and Home Palliative Care Services in India
- How to Have a Goals-of-Care Conversation With Your Doctor
- Pain Control at Home: What's Possible and What to Ask For
- Palliative Care Is Not Giving Up: Clearing the Biggest Myth
- Should You Ask How Long You Have Left?
- Supporting a Family Member in Their Last Months
- What 'Best Supportive Care' Actually Means
- When Is It Right to Stop Cancer Treatment?
Special Populations & Comorbidities
- Cancer Treatment After an Organ Transplant
- Cancer Treatment for Patients on Dialysis
- Cancer Treatment in Patients With Past or Active Tuberculosis
- Growth, Puberty and School During Childhood Cancer Treatment
- Hepatitis B and C Reactivation Risk During Cancer Treatment
- Managing Diabetes While on Targeted Therapy
- Obesity, Underweight and Dosing: Does Body Size Change the Dose?
- Paediatric Targeted Therapy: What Parents Need to Know
- Targeted Therapy With Autoimmune Disease
- Targeted Therapy With Chronic Kidney Disease
- Targeted Therapy With Existing Heart Disease
- Targeted Therapy With Liver Disease or Cirrhosis
- Targeted Therapy for Adolescents and Young Adults
- Targeted Therapy for Patients With Mental Illness or Dementia
- Targeted Therapy in HIV-Positive Patients
- Targeted Therapy in Patients Over 75: Is It Worth It?
- Treating Patients With Poor Performance Status
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is PALB2 as dangerous as BRCA1?
Not quite, though the difference is smaller than many people expect. BRCA1 lifetime breast cancer risk is typically placed in the range of six in ten to eight in ten by NCCN and ASCO. PALB2 is placed in the range of one in three to one in two — substantially above average, and high enough to warrant structured surveillance and a risk-reduction conversation, but generally below BRCA1. Your family history matters: a PALB2 carrier with multiple affected relatives sits higher within that range than one with no family history of breast cancer.
Can I have surgery to reduce my risk if I carry PALB2?
Risk-reducing mastectomy is an option that some PALB2 carriers discuss with their team. NCCN treats it as an individualised decision — not a standard recommendation applied to all PALB2 carriers. Whether it is right for you depends on your personal risk estimate, your family history, your age, and your own priorities. The conversation is worth having, and a specialist breast clinic alongside a genetic counsellor is the right setting for it. Surveillance and chemoprevention are alternatives that many PALB2 carriers choose instead.
My test found a MUTYH mutation — do I need the same monitoring as my relative with BRCA1?
No. MUTYH and BRCA1 raise the risk of different cancers through entirely different mechanisms. MUTYH primarily raises colorectal cancer risk, particularly if you carry two changed copies. BRCA1 primarily raises breast and ovarian cancer risk. Your relative's protocol — likely involving breast MRI, mammography, and possibly gynaecological surveillance — does not apply to you. You need a bowel surveillance plan specific to MUTYH, with frequency determined by whether you carry one or two changed copies.
Does a PALB2 mutation affect men?
Yes. Male PALB2 carriers have an elevated risk of breast cancer — rarer in men than in women, but the relative increase is meaningful. There is also emerging evidence of a modestly elevated pancreatic cancer risk in PALB2 carriers of both sexes. NCCN recommends that male PALB2 carriers discuss breast awareness and periodic clinical examination with their team. The exact surveillance schedule for men is less established than for women and is a conversation worth having with a genetic counsellor.
I carry only one MUTYH copy — is that still serious?
One changed MUTYH copy (monoallelic) carries a modestly elevated colorectal cancer risk, meaningfully lower than carrying two changed copies. NCCN guidance for monoallelic carriers typically involves colonoscopy starting no later than 40, at intervals based on findings and family history — not the intensive surveillance required for biallelic carriers. The important follow-up question is whether any of your relatives also carry one copy, because a child of two monoallelic carriers can inherit both and be at the higher biallelic risk level.
Will health insurance in India cover screening for PALB2 or ATM?
Coverage varies by policy and changes year on year, so the most reliable answer comes from your insurer directly, in writing. Government health schemes in Telangana and Andhra Pradesh may cover some genetic testing and surveillance; ask your treating team what documentation the scheme requires. CION centres can provide the written genetic report and physician letter that insurers and government schemes typically request when considering a surveillance claim.